Saturday, July 11, 2026

Drug profile · INN

sulfanilamide

sulfanilamide (AVC) is a bacterial dihydropteroate synthase inhibitor. Route of administration: vaginal. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — sulfanilamide
US status
approved
Class
Route
VAGINAL
Patents
0
Programs
0
Data quality
0.84

Quick answer

sulfanilamide (AVC) is a bacterial dihydropteroate synthase inhibitor. Route of administration: vaginal. Current US regulatory status: approved.

Key facts

INN sulfanilamide
Brand AVC
Mechanism Bacterial dihydropteroate synthase inhibitor
Target Dihydropteroate synthase
Route VAGINAL
Formulation SUPPOSITORY

Mechanism of action

Bacterial dihydropteroate synthase inhibitor

Primary target: Dihydropteroate synthase

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. dapsone Dihydropteroate synthase 1 inhibitor
  2. sulfamethoxazole Bacterial dihydropteroate synthase inhibitor
  3. mafenide acetate Bacterial dihydropteroate synthase inhibitor
  4. silver sulfadiazine Bacterial dihydropteroate synthase inhibitor
  5. sulfacetamide sodium Bacterial dihydropteroate synthase inhibitor
  6. sulfadiazine Bacterial dihydropteroate synthase inhibitor

Frequently asked questions

What is sulfanilamide?

sulfanilamide (AVC) is a bacterial dihydropteroate synthase inhibitor. Route of administration: vaginal. Current US regulatory status: approved.

What is the brand name for sulfanilamide?

AVC is a marketed brand name for sulfanilamide. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of sulfanilamide?

sulfanilamide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.